Literature DB >> 6354101

Inhibitor of prostacyclin production in sporadic haemolytic uraemic syndrome.

M Levin, K B Elkon, T J Nokes, A M Buckle, M J Dillon, R M Hardisty, T M Barratt.   

Abstract

Prostacyclin (PGI2) production was diminished when rat aortic rings were incubated with plasma from 5 of 6 patients with the sporadic form of haemolytic uraemic syndrome but was normal in the presence of plasma from 7 patients with the epidemic form of haemolytic uraemic syndrome or from patients with other renal diseases. The reduced PGI2 production was caused by an unstable inhibitor, extractable into polar lipid solvents, in sporadic haemolytic uraemic plasma. These results suggest that there may be at least 2 different pathogenetic mechanisms in epidemic and sporadic haemolytic uraemic syndrome and that the reduced PGI2 production observed in the sporadic type is due to an inhibitor of PGI2 production rather than a deficiency of stimulating factors.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6354101      PMCID: PMC1628234          DOI: 10.1136/adc.58.9.703

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  16 in total

1.  Localisation and stimulation of prostacyclin production in vascular cells.

Authors:  D E MacIntyre; J D Pearson; J L Gordon
Journal:  Nature       Date:  1978-02-09       Impact factor: 49.962

2.  The hemolytic-uremic syndrome.

Authors:  C A Gianantonio; M Vitacco; F Mendilaharzu; G E Gallo; E T Sojo
Journal:  Nephron       Date:  1973       Impact factor: 2.847

3.  Treatment of thrombotic thrombocytopenic purpura with plasma.

Authors:  J J Byrnes; M Khurana
Journal:  N Engl J Med       Date:  1977-12-22       Impact factor: 91.245

Review 4.  Hemolytic-uremic syndrome. Current concepts and management.

Authors:  J S Fong; J P de Chadarevian; B S Kaplan
Journal:  Pediatr Clin North Am       Date:  1982-08       Impact factor: 3.278

Review 5.  Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature.

Authors:  R L Ridolfi; W R Bell
Journal:  Medicine (Baltimore)       Date:  1981-11       Impact factor: 1.889

6.  Normal prostacyclin-like activity in thrombotic thrombocytopenic purpura.

Authors:  M Pini; C Manotti; R Quintavalla; A G Dettori
Journal:  Thromb Haemost       Date:  1981-08-28       Impact factor: 5.249

7.  Hemolytic uremic syndrome in families.

Authors:  B S Kaplan; R W Chesney; K N Drummond
Journal:  N Engl J Med       Date:  1975-05-22       Impact factor: 91.245

8.  Accelerated prostacyclin degradation in the thrombotic thrombocytopenic purpura.

Authors:  Y C Chen; B McLeod; E R Hall; K K Wu
Journal:  Lancet       Date:  1981-08-08       Impact factor: 79.321

9.  Haemolytic-uraemic syndrome: an analysis of prognostic features.

Authors:  R S Trompeter; R Schwartz; C Chantler; M J Dillon; G B Haycock; R Kay; T M Barratt
Journal:  Arch Dis Child       Date:  1983-02       Impact factor: 3.791

10.  Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation.

Authors:  S Moncada; E A Higgs; J R Vane
Journal:  Lancet       Date:  1977-01-01       Impact factor: 79.321

View more
  21 in total

1.  Prostacyclin concentrations in haemolytic uraemic syndrome after acute shigellosis.

Authors:  C M Taylor; C J Lote
Journal:  Arch Dis Child       Date:  1992-11       Impact factor: 3.791

Review 2.  Glomerular fibrin deposition and removal.

Authors:  J M Bergstein
Journal:  Pediatr Nephrol       Date:  1990-01       Impact factor: 3.714

Review 3.  Pathogenesis of the hemolytic uremic syndromes: current concepts.

Authors:  B S Kaplan; V V Vedaranayanan
Journal:  Indian J Pediatr       Date:  1988 Jul-Aug       Impact factor: 1.967

4.  Abnormalities of vascular prostaglandins in Henoch-Schönlein purpura.

Authors:  S Turi; J J Belch; T J Beattie; C D Forbes
Journal:  Arch Dis Child       Date:  1986-02       Impact factor: 3.791

5.  Prostacyclin deficiency in a young woman with recurrent thrombosis.

Authors:  J G Lanham; M Levin; Z Brown; A E Gharavi; P A Thomas; G C Hanson
Journal:  Br Med J (Clin Res Ed)       Date:  1986-02-15

6.  Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology.

Authors:  C Loirat; E Sonsino; N Hinglais; J P Jais; P Landais; J Fermanian
Journal:  Pediatr Nephrol       Date:  1988-07       Impact factor: 3.714

7.  Haemolytic-uraemic syndrome presenting as an acute abdomen.

Authors:  P M Lamont; A I Davidson
Journal:  Postgrad Med J       Date:  1987-09       Impact factor: 2.401

8.  Haemolytic uraemic syndrome and the Thomsen Friedenreich antigen.

Authors:  M E McGraw; M Lendon; R F Stevens; R J Postlethwaite; C M Taylor
Journal:  Pediatr Nephrol       Date:  1989-04       Impact factor: 3.714

9.  Plasma factors influencing PGI2-like activity in patients with IgA nephropathy and Henoch-Schönlein purpura.

Authors:  S Túri; J Nagy; I Haszon; Z Havass; M Németh; C Bereczki
Journal:  Pediatr Nephrol       Date:  1989-01       Impact factor: 3.714

10.  Prostacyclin concentrations in haemolytic uraemic syndrome after acute shigellosis in children.

Authors:  A N Alam; N M Abdal; M A Wahed; B Rao; C A Kawser; M Hoque; M M Rahaman
Journal:  Arch Dis Child       Date:  1991-10       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.